NCT03666442View on ClinicalTrials.gov

Early Evaluation of Chemosensitivity for Low/Intermediated-risk Mid-low Stage II/III Rectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

January 1, 2020

Study Completion Date

January 1, 2022

Conditions
Rectal Cancer
Interventions
DRUG

XELOX

Xelox chemotherapy,that oxaliplatin 130mg/m2 d1,capecitabine 1000mg/m2 twice daily d1-14,every 3 weeks

Trial Locations (1)

610041

Guoxue Road 37#,West China Hospital, Chengdu

All Listed Sponsors
lead

West China Hospital

OTHER

NCT03666442 - Early Evaluation of Chemosensitivity for Low/Intermediated-risk Mid-low Stage II/III Rectal Cancer | Biotech Hunter | Biotech Hunter